Payment overview · 2025
General Payments
$280.53
15 reported records · 7 companies
Healthcare provider profile · identity verified
Alan Bryson, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · LAUREL, MS · NPI 1740675487
Verified facts
What the public records show
CMS Open Payments records show Alan Bryson, PA received $280.53 in general payments during 2025 across 15 reported records.
Novo Nordisk Inc accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $94.13 | 33.5% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $53.15 | 18.9% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $44.95 | 16.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.14 | 12.2% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $22.07 | 7.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.55 | 6.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.54 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $280.53 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $53.15 | 3 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $44.95 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.37 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $34.14 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 82 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 131 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 52 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 125 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
82 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 644 | 180 |
| Atorvastatin Calcium | Atorvastatin Calcium | 486 | 151 |
| Losartan Potassium | Losartan Potassium | 351 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 318 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 296 | 95 |
| Metformin Hcl | Metformin Hcl | 294 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 273 | 66 |
| Omeprazole | Omeprazole | 263 | 83 |
| Gabapentin | Gabapentin | 255 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 83 |
| Diclofenac Sodium | Diclofenac Sodium | 224 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 59 |
| Lisinopril | Lisinopril | 195 | 54 |
| Potassium Chloride | Potassium Chloride | 181 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 59 |
| Alendronate Sodium | Alendronate Sodium | 171 | 52 |
| Meloxicam | Meloxicam | 168 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 162 | 42 |
| Furosemide | Furosemide | 137 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 67 |
| Jardiance | Empagliflozin | 131 | 30 |
| Sertraline Hcl | Sertraline Hcl | 126 | 38 |
| Ozempic | Semaglutide | 125 | 27 |
| Trazodone Hcl | Trazodone Hcl | 119 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 28 |
| Glimepiride | Glimepiride | 111 | 31 |
| Montelukast Sodium | Montelukast Sodium | 110 | 34 |
| Allopurinol | Allopurinol | 109 | 31 |
| Metformin Hcl Er | Metformin Hcl | 102 | 38 |
| Eliquis | Apixaban | 98 | 32 |
| Simvastatin | Simvastatin | 91 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 25 |
| Carvedilol | Carvedilol | 84 | 29 |
| Farxiga | Dapagliflozin Propanediol | 82 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 17 |
| Spironolactone | Spironolactone | 71 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 25 |
| Donepezil Hcl | Donepezil Hcl | 64 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 17 |
| Bupropion Xl | Bupropion Hcl | 55 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | suppressed |
| Linzess | Linaclotide | 52 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 17 |
| Sucralfate | Sucralfate | 52 | 15 |
| Clonidine Hcl | Clonidine Hcl | 51 | 14 |
| Tramadol Hcl | Tramadol Hcl | 50 | 26 |
| Ezetimibe | Ezetimibe | 48 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Famotidine | Famotidine | 43 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 14 |
| Meclizine Hcl | Meclizine Hcl | 41 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 14 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 22 |
| Irbesartan | Irbesartan | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 14 |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 24 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 28 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 26 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 27 | 11 |
| Victoza 2-Pak | Liraglutide | 27 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Baclofen | Baclofen | 25 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 16 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 12 |
| Methocarbamol | Methocarbamol | 18 | 16 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Prednisone | Prednisone | 15 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $280.53 · 15 records | Novo Nordisk Inc | FARXIGA, JARDIANCE, Kerendia, LINZESS, Ozempic, QUTENZA, Rybelsus, SPRAVATO | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error